outcome is due to a dose-dependent effect or it can be attributed more specifically to a drug interaction.This study aims to investigate if the rate of renal function decline in advanced CKD patients is associated to the doses of RAS blockers, and, if dual RAS blockade worsens renal function independently of major confounding factors. METHODS: Retrospective, observational study in an incident cohort of adult patients with CKD stage 4 or 5 not on dialysis, treated with RAS blockers for at least 6 months prior to the study inclusion. Inclusion criteria were: having at least three consecutive measurements of estimated glomerular filtration rate (eGFR) in a follow-up period > 3 months. Decline in renal function was estimated as the slope of the individual linear regression line of eGFR over follow-up time. Equipotent doses of RAS blockers were normalized for a body weight of 70 kg or a body surface area of 1.73 m2 (END-RAS). For example, the END-RAS in a patient with a body weight of 70 kg receiving a daily dose of enalapril 20 mg or valsartan 160 mg was counted as 1, whereas if he/she received dual RAS blockade with both drugs the END-RAS was then of 2, and so on.Associations of END-RAS or dual RAS blockade with the rate of renal function decline were analysed by uni-or multivariate linear regression models, accounting for major confounding variables (demographic, co-morbidity, blood pressure, baseline eGFR, serum bicarbonate, proteinuria, and concurrent medication). RESULTS: The study group consisted of 813 patients (mean age 64614 years, 430 males) with a mean eGFR 14.964.2 ml/min/1,73 m2. 729 patients were on RAS blockade monotherapy and 84 on dual RAS blockade. Median END-RAS in the whole group was 0.91 (I.Q. ranges 0.69 -1.20). Patients on dual RAS blockade had significantly higher END-RAS than the rest of study patients (1.5260.49 vs. 0.9360.44; p<0.0001). In univariate linear regression, END-RAS blockers were significantly correlated with eGFR decline (beta ¼ -0.149; p<0.0001). Patients on dual RAS blockade showed a significantly faster decline of renal function than the rest of the study patients (-6.1965.57 vs. -3.0465.37 ml/min/1,73 m2/year, p<0.0001). By multivariate linear regression, while dual RAS blockade remained independent and significantly associated with faster renal function decline (beta ¼ -0.099; p¼0.003), END-RAS (normalized either for body weight or surface area) did not reach statistical significance. CONCLUSIONS: END-RAS are significantly associated with the rate of renal function decline in advanced CKD patients. However, the detrimental effect of dual RAS blockade on CKD progression seems to be independent of END-RAS and other major confounding factors. Internal Medicine Department H, Soroka University Medical Center, Beer Sheva, Israel INTRODUCTION AND AIMS: Pregnancy-related complications such as gestational diabetes and pre-eclampsia pose a risk for future maternal atherosclerotic morbidity. This study was aimed to demonstrate whether an association exists between five types of blood tests (creatinine, urea, uric acid, glucose, and potassium) during pregnancy and the risk for future maternal cardiovascular morbidity. METHODS: The study population included women who gave birth at the Soroka University Medical Center (SUMC) between the years 2000-2013. This population included women who were subsequently hospitalized due to atherosclerotic morbidity during the study period and age-matched controls. Only women for whom at least one test result was available for all five test types-potassium, uric acid, creatinine, urea, and glucose during their pregnancies were included. The follow-up period was until either hospitalization or the end of study period. Cox regression was performed in order to demonstrate the relationship between cardiovascular hospitalization and upper quartile blood test values during pregnancy. RESULTS: The final analysis included 4115 women who met the inclusion criteria. Of these, 212 were defined as the hospitalized group (cases), and 3903 women served as the non-hospitalized group (controls). In a Cox regression model the values in the upper quartile of potassium (HR ¼1.48 CI 1.09-2.01 p¼0.013), creatinine (HR¼1.86 CI 1.37-2.53 P<0.001) and urea (HR¼1.60 CI 1.17-2.19 P¼0.003) measured during pregnancy were associated with an increased risk for hospitalization due to cardiovascular and atherosclerotic morbidity. Women who had two blood tests in upper quartile during pregnancy had a risk of 1.65 (CI 1.06-2.56 P¼0.026) to have future cardiovascular hospitalization. Women who had three or more blood tests in upper quartile during
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SP269 BLOOD TESTS DURING PREGNANCYTHAT MAY PREDICT LONG-TERM CARDIOVASCULAR MORBIDITY

INTRODUCTION AND AIMS:
Pregnancy-related complications such as gestational diabetes and pre-eclampsia pose a risk for future maternal atherosclerotic morbidity. This study was aimed to demonstrate whether an association exists between five types of blood tests (creatinine, urea, uric acid, glucose, and potassium) during pregnancy and the risk for future maternal cardiovascular morbidity. METHODS: The study population included women who gave birth at the Soroka University Medical Center (SUMC) between the years 2000-2013. This population included women who were subsequently hospitalized due to atherosclerotic morbidity during the study period and age-matched controls. Only women for whom at least one test result was available for all five test types-potassium, uric acid, creatinine, urea, and glucose during their pregnancies were included. The follow-up period was until either hospitalization or the end of study period. Cox regression was performed in order to demonstrate the relationship between cardiovascular hospitalization and upper quartile blood test values during pregnancy. RESULTS: The final analysis included 4115 women who met the inclusion criteria. Of these, 212 were defined as the hospitalized group (cases), and 3903 women served as the non-hospitalized group (controls). In a Cox regression model the values in the upper quartile of potassium (HR ¼1.48 CI 1.09-2.01 p¼0.013), creatinine (HR¼1.86 CI 1.37-2.53 P<0.001) and urea (HR¼1.60 CI 1.17-2.19 P¼0.003) measured during pregnancy were associated with an increased risk for hospitalization due to cardiovascular and atherosclerotic morbidity. Women who had two blood tests in upper quartile during pregnancy had a risk of 1.65 (CI 1.06-2.56 P¼0.026) to have future cardiovascular hospitalization. Women who had three or more blood tests in upper quartile during pregnancy had a considerable risk of 3.32 (CI 2.19-5.04 p<0.001) for cardiovascular hospitalization. CONCLUSIONS: Routine blood tests during pregnancy can predict future cardiovascular morbidity among women with no overt clinical gestational complications. Copeptin analysis is an alternative to AVP measurement. This study is attempted to demonstrate reduction of plasma AVP levels after a period of hydration and to assess its translation to reduced urinary albumin excretion in early stages of CKD. i)To compare: Baseline copeptin levels in the plasma of various study groups 1)normal individuals 2)Type 2 diabetes mellitus patients with microalbuminuria 3)patients with systemic hypertension ii)To assess the change in plasma copeptin values after a self monitored water load in the above groups iii)To assess the change in proteinuria after this period of water load METHODS: Comparative cross sectional study. Duration:1year. 90 male patients were selected from the clinic and grouped into 3. Inclusion criteria Group 1 30 healthy subjects in the same age group who met the following criteria 1.No history of diabetes 2.BMI<28kg/m 2 3.No hypertension 4.Not on any long term drugs 5.No dyslipidemia, no history of cardiovascular events 6.Non smoker, non alcoholic 7.No history of renal disease Group 2 25 male Type 2 diabetes patients on oral hypoglycemic agents with moderately increased albuminuria in the age group 18-40 years with i)well controlled diabetes ii) Moderately increased albuminuria. All patients were on ACEI/ARBs Group 3 25 male patients with hypertension and moderately increased albuminuria in the age group 18-40 yrs Exclusion Criteria i) No written consent ii) subjects <18 or> 40 years iii) subjects with accelerated hypertension during study iv)abnormal baseline osmolality levels v)advanced diabetic kidney disease vi)systolic BP>180mmHg and diastolic BP>110 mmHg vii)other intercurrent illness. 80 male subjects were studied. Baseline glycemic control status, albuminuria, plasma osmolality, plasma copeptin, S. uric acid levels were assessed. Participants were instructed to maintain a high hydration state by taking 2-2.5L of free water daily for the next 3months and to avoid caffeine and smoking. At the end of 3 months subjects were reassessed. RESULTS: Observations at the baseline suggested a higher plasma osmolality and copeptin levels in group2 and 3. One way ANOVA applied to the groups proved the difference in copeptin and S. osmolality at baseline to be statistically significant. 
SP270 GENETIC SUSCEPTIBILITY TO TGF-BETA INDUCED RENAL FIBROSIS IS ASSOCIATED WITH ALTERED MIR-199 EXPRESSION
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